Notice type: 3rd Party Publications
Problem Or Issue:
Important Safety Information communication from Janssen Ireland on the risk of exfoliative dermatitis and skin exfoliation with Stelara (Ustekinumab).
Important Safety Information - Stelara (Ustekinumab)